These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 21763790)

  • 1. Anti-CD 20 monoclonal antibody (rituximab) treatment for inflammatory ocular diseases.
    Miserocchi E; Pontikaki I; Modorati G; Gattinara M; Meroni PL; Gerloni V
    Autoimmun Rev; 2011 Nov; 11(1):35-9. PubMed ID: 21763790
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rituximab for noninfectious uveitis.
    Miserocchi E; Modorati G
    Dev Ophthalmol; 2012; 51():98-109. PubMed ID: 22517208
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of severe uveitis associated with juvenile idiopathic arthritis with anti-CD20 monoclonal antibody (rituximab).
    Heiligenhaus A; Miserocchi E; Heinz C; Gerloni V; Kotaniemi K
    Rheumatology (Oxford); 2011 Aug; 50(8):1390-4. PubMed ID: 21378109
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Treatment of pemphigus with rituximab].
    Li J; Zheng HY; Liu YH
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2009 Feb; 31(1):107-10. PubMed ID: 19317073
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The efficacy and safety of rituximab in refractory pemphigus: a review of case reports.
    Allen KJ; Wolverton SE
    J Drugs Dermatol; 2007 Sep; 6(9):883-9. PubMed ID: 17941359
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adult refractory idiopathic thrombocytopenic purpura.
    Braendstrup P; Bjerrum OW; Nielsen OJ; Jensen BA; Clausen NT; Hansen PB; Andersen I; Schmidt K; Andersen TM; Peterslund NA; Birgens HS; Plesner T; Pedersen BB; Hasselbalch HC
    Am J Hematol; 2005 Apr; 78(4):275-80. PubMed ID: 15795920
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The clinical and biological role of CD20 membrane antigen modulation under immunotherapy with anti-CD20 monoclonal antibody rituximab in lymphoprolipherative neoplastic disorders.
    Musto P; D'Auria F
    Expert Opin Biol Ther; 2011 May; 11(5):551-7. PubMed ID: 21385115
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-CD20 monoclonal antibodies and their use in adult autoimmune hematological disorders.
    Dierickx D; Delannoy A; Saja K; Verhoef G; Provan D
    Am J Hematol; 2011 Mar; 86(3):278-91. PubMed ID: 21328427
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The role of rituximab in the treatment of ANCA-associated systemic vasculitis].
    Roccatello D; Vangelista A; Pani A
    G Ital Nefrol; 2011; 28(5):474-88. PubMed ID: 22028261
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma].
    Huang HQ; Bu Q; Xia ZJ; Lin XB; Wang FH; Li YH; Peng YL; Pan ZH; Wang SS; Lin TY; Jiang WQ; Guan ZZ
    Ai Zheng; 2006 Apr; 25(4):486-9. PubMed ID: 16613686
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Retrospective case review of pediatric patients with uveitis treated with infliximab.
    Rajaraman RT; Kimura Y; Li S; Haines K; Chu DS
    Ophthalmology; 2006 Feb; 113(2):308-14. PubMed ID: 16406545
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Targeting CD20 in rheumatoid arthritis].
    Saito K; Tanaka Y
    Nihon Rinsho; 2007 Jul; 65(7):1243-9. PubMed ID: 17642239
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rituximab for uveitis.
    Miserocchi E; Pontikaki I; Modorati G; Bandello F; Meroni PL; Gerloni V
    Ophthalmology; 2011 Jan; 118(1):223-4. PubMed ID: 21199719
    [No Abstract]   [Full Text] [Related]  

  • 14. Differential effectiveness of etanercept and infliximab in the treatment of ocular inflammation.
    Galor A; Perez VL; Hammel JP; Lowder CY
    Ophthalmology; 2006 Dec; 113(12):2317-23. PubMed ID: 16996615
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rituximab: emerging treatment strategies of immune-mediated glomerular disease.
    Kattah AG; Fervenza FC
    Expert Rev Clin Immunol; 2012 Jul; 8(5):413-21. PubMed ID: 22882216
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor necrosis factor alpha blockade with infliximab for refractory uveitis and scleritis.
    Murphy CC; Ayliffe WH; Booth A; Makanjuola D; Andrews PA; Jayne D
    Ophthalmology; 2004 Feb; 111(2):352-6. PubMed ID: 15019389
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term observation of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis treated with rituximab.
    Stasi R; Stipa E; Del Poeta G; Amadori S; Newland AC; Provan D
    Rheumatology (Oxford); 2006 Nov; 45(11):1432-6. PubMed ID: 16632482
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systemic eight-cycle anti-CD20 monoclonal antibody (rituximab) therapy in primary cutaneous B-cell lymphomas--an applicational observation.
    Gellrich S; Muche JM; Wilks A; Jasch KC; Voit C; Fischer T; Audring H; Sterry W
    Br J Dermatol; 2005 Jul; 153(1):167-73. PubMed ID: 16029344
    [TBL] [Abstract][Full Text] [Related]  

  • 19. B-cell depletion with rituximab as treatment for immune hemolytic anemia and chronic thrombocytopenia.
    Zaja F; Iacona I; Masolini P; Russo D; Sperotto A; Prosdocimo S; Patriarca F; de Vita S; Regazzi M; Baccarani M; Fanin R
    Haematologica; 2002 Feb; 87(2):189-95. PubMed ID: 11836170
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Monoclonal antibody therapy for uveitis].
    Kawashima H
    Nihon Rinsho; 2002 Mar; 60(3):556-62. PubMed ID: 11904973
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.